Klaudyne Hong, Founder - AI Improving Clinical Outcomes

<p><span style="font-size: 12pt;"><span style= "color: #e67e23;"><strong>Join Sal Daher's Investment Syndicate:</strong></span> <strong><a href= "https://www.angelinvestboston.com/our-syndicates">Click to Subscribe</a></strong></span></p> <p>The sense of purpose and focus that led Klaudyne Hong to do her PhD at MIT in two years helped her turn a chance comment during a fly-fishing trip into a groundbreaking startup. Peach IntelliHealth is building AI for acute medical care. Her project was seeded by the Government of Singapore where she found great help in building her data set. She’s now seeking FDA approval.</p> <p>Highlights include:</p> <ul> <li>Sal Daher Introduces Klaudyne Hong, PhD, Founder of Peach Intellihealth</li> <li>What Peach Intellihealth Does</li> <li>Peach Intellihealth’s AI Can Predict a Patient’s Response to Treatment</li> <li>The Founding Story of Peach Intellihealth</li> <li>“So, if you don't remember anything about what I say today, remember the next point. It's the highlight of the show, okay? I actually caught two striped bass that morning.”</li> <li>“And we started then doing a historical analysis, and we realized that our algorithms actually fit that data very nicely.”</li> <li>Peach’s AI Got Regulatory Approval in Singapore – Now Replicating Pivotal Study in the U.S.</li> <li>“Sepsis, by the way, is the most expensive health care condition, hospitalized condition, in the U.S.”</li> <li>“If someone's going to go into cardiac arrest, and you know it several hours in advance, you can make a huge difference.”</li> <li>Current Status of Peach Intellihealth</li> <li>Funding for Peach Intellihealth – the Government of Singapore Came in as a Seed Investor</li> <li>“I grew up in Singapore, and I left when I was relatively young. So, I was as an undergrad in California.”</li> <li>Her Favorite Show “Cheers” Showed Boston in Such a Good Light that Klaudyne Chose to Apply to MIT</li> <li>“…my thesis…was about controlling gene expression for gene therapy applications.”</li> <li>Klaudyne’s Two-Year Ph